Abstract

The present invention relates to methods and pharmaceutical compositions of inducing immune tolerance by mucosal vaccination with Fc-coupled antigens. In particular, the present invention relates to a method for inducing tolerance to one antigen of interest in a subject in need thereof, comprising the mucosal administration to the subject of a therapeutically effective amount of a recombinant chimeric construct comprising a FcRn targeting moiety and an antigen-containing moiety.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection

Abstract

The invention relates to the use of HNRNPC-expressing vectors for preventing and/or treating a tauopathy, such as Alzheimer's disease. The invention relates to methods for detecting a risk of developing a tauopathy such Alzheimer's disease in a patient, comprising the step of detecting the level of HNRNPC in a biological sample obtained from said patient.

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Abstract

The present invention relates to compositions and methods for treating myotonic dystrophy.

IPC Classes  ?

• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 35/761 - Adenovirus

Abstract

The invention relates to the regulated expression of a chimeric antigen receptor (CAR) within a lentiviral vector. The CAR comprises a hook-binding domain that interacts with a hook, preferably encoded by the same lentiviral vector, which prevents proper processing and release of the CAR to the cell membrane. The invention encompasses vectors, methods of making the vectors, and methods of using them, including medicinal uses. The vectors can be used for administration to humans to induce immune responses and to treat cancers and tumors.

IPC Classes  ?

• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies

Abstract

Faecalibacterium prausnitzii species selected from a bacterial strain belonging to one of the phylogroups I, II and III, for use in the treatment and/or prevention of visceral abdominal pain in an individual. The present invention also concerns compositions comprising said bacterial strains as well as specific strains as such.

IPC Classes  ?

• A61K 35/741 - Probiotics
• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]

Abstract

The invention relates to a device (5) for determining the quantities of filling liquid and vasopressor to be administered to a patient by means of respectively a first dispenser (3) and a second dispenser (4), characterised in that the device (5) is designed to determine a quantity of filling liquid and a quantity of vasopressor, on the basis of the previously measured blood pressure of a patient, such that said quantities depend on the ratio between quantities of filling liquid and vasopressor that have already been administered over a given period.

IPC Classes  ?

• A61B 5/021 - Measuring pressure in heart or blood vessels
• A61B 5/029 - Measuring blood output from the heart, e.g. minute volume
• A61M 5/142 - Pressure infusion, e.g. using pumps

Abstract

The present invention relates to improved constructs comprising the short and long Rod- Derived Cone Viability Factors and to methods for treating retinal degenerative diseases.

IPC Classes  ?

• C12N 15/86 - Viral vectors
• C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy

Abstract

A method of analyzing a visual field of an individual comprises the following steps: - measuring (S4) a first visual field (VF1) of said individual for a first set of oculo-postural parameters of said individual when said individual performs a first task; - measuring (S6) at least one additional visual field (VFi) of said individual for one additional set of said oculo-postural parameters of said individual when said individual performs an additional task; - determining (S8) a functional visual space based on said first visual field (VF1) and said at least one additional visual field (VFi), said functional visual space being an envelope of said first visual field and said at least one additional visual field. The additional task differs from said first task and/or said additional set of oculo-postural parameters differs from said first set of oculo-postural parameters. A corresponding ophthalmic lens is also proposed.

IPC Classes  ?

• A61B 3/024 - Subjective types, i.e. testing apparatus requiring the active assistance of the patient for determining the visual field, e.g. perimeter types

Abstract

The present invention relates to novel phytopharmaceutical compounds, in particular to elicitors of natural plant defenses, to compositions comprising such compounds, and to uses thereof. The invention also relates in particular to a process for producing the novel phytopharmaceutical compounds.

IPC Classes  ?

• A01N 43/16 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atom with one hetero atom six-membered rings with oxygen as the ring hetero atom
• A01N 65/00 - Biocides, pest repellants or attractants, or plant growth regulators containing material from algae, lichens, bryophyta, multi-cellular fungi or plants, or extracts thereof

Abstract

An electromagnetic sensing device (400) for detecting magnetic nanoparticles, comprising: a reference microfiuidic reservoir (RR) to receive a reference substance with magnetic nanoparticles; an analyte microfiuidic reservoir (AR) to receive an analyte and magnetic nanoparticles; a first excitation magnetic coil (HF1) to subject the reference microfiuidic reservoir (RR) to an alternating magnetic field at a first frequency; a second excitation magnetic coil (HF2) to subject the analyte microfiuidic reservoir (AR) to an alternating magnetic field at the first frequency; a third excitation magnetic coil (BFl) to subject the reference microfiuidic reservoir (RR) to an alternating magnetic field at a second frequency distinct from the first frequency; a fourth excitation magnetic coil (BF2) to subject the analyte microfiuidic reservoir (AR) to an alternating magnetic field at the second frequency; a first detection magnetic coil (D1) to detect a response magnetic field of the magnetic nanoparticles in the reference microfiuidic reservoir (RR); a second detection magnetic coil (D2) to detect a response magnetic field of the magnetic nanoparticles in the analyte microfiuidic reservoir (AR). The electromagnetic sensing device is structured according to a plurality of superimposed layers (L1, L2, L3, L4, L5), comprising at least three coil layers (L2, L3, L4, L5) and a reservoir layer (L1).

IPC Classes  ?

• G01N 27/74 - Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating magnetic variables of fluids

Abstract

LMNALMNALMNA-related dilated cardiomyopathies.

IPC Classes  ?

• A61K 31/00 - Medicinal preparations containing organic active ingredients
• A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
• A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
• A61K 31/4468 - Non-condensed piperidines, e.g. piperocaine having a nitrogen atom directly attached in position 4, e.g. clebopride, fentanyl
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61P 9/00 - Drugs for disorders of the cardiovascular system

Abstract

The invention relates to a process for manufacturing at least one implant for focal electrical stimulation of a nervous structure, said implant being of the type including in a supporting structure a network of cavities at the bottom of which are placed microelectrodes, the cavities being bounded by walls erected and located around the microelectrodes, the supporting structure being produced beforehand by implementing the following steps: deposition and etching, in a planar manner, on an insulating substrate, of electrical contacts, of electrical tracks and of microelectrodes, first tracks electrically connecting the microelectrodes and the electrical contacts, second electrical tracks being electrically connected to a ground.

IPC Classes  ?

• A61N 1/05 - Electrodes for implantation or insertion into the body, e.g. heart electrode
• A61N 1/02 - ElectrotherapyCircuits therefor Details
• A61N 1/36 - Applying electric currents by contact electrodes alternating or intermittent currents for stimulation, e.g. heart pace-makers
• H01B 5/14 - Non-insulated conductors or conductive bodies characterised by their form comprising conductive layers or films on insulating-supports
• H01B 13/00 - Apparatus or processes specially adapted for manufacturing conductors or cables
• H05K 3/06 - Apparatus or processes for manufacturing printed circuits in which the conductive material is applied to the surface of the insulating support and is thereafter removed from such areas of the surface which are not intended for current conducting or shielding the conductive material being removed chemically or electrolytically, e.g. by photo-etch process
• H05K 3/46 - Manufacturing multi-layer circuits

Abstract

The invention relates to a method for characterising bone, the method comprising the steps of receiving (102) ultrasonic wave echo signals transmitted into a body, determining (104) a speed of sound in the body's non-bone biological tissue, locating (106) a first demarcation curve between non-bone biological tissue and bone in an image of the body constructed during said determining step, and determining (108) a speed of sound in bone. The steps of determining speed include constructing images from the signals, and a metric calculation indicative of a focus quality in the constructed images.

IPC Classes  ?

• A61B 8/08 - Clinical applications

Abstract

A coated metallic substrate and fabrication method The present invention relates to a coated metallic substrate comprising, at least; one layer of oxides, such layer being directly topped by an intermediate coating layer comprising Fe, Ni, Cr and Ti wherein the amount of Ti is above or equal to 5 wt.% and wherein the following equation is satisfied: 8 wt.% < Cr +Ti < 40 wt.%, the balance being Fe and Ni, such intermediate coating layer being directly topped by a coating layer being an anticorrosion metallic coating.

IPC Classes  ?

• C23C 28/00 - Coating for obtaining at least two superposed coatings either by methods not provided for in a single one of main groups , or by combinations of methods provided for in subclasses and
• B32B 15/00 - Layered products essentially comprising metal
• C25D 5/36 - Pretreatment of metallic surfaces to be electroplated of iron or steel
• C23C 14/02 - Pretreatment of the material to be coated
• C23C 14/16 - Metallic material, boron or silicon on metallic substrates or on substrates of boron or silicon
• C23C 14/35 - Sputtering by application of a magnetic field, e.g. magnetron sputtering
• C22C 38/00 - Ferrous alloys, e.g. steel alloys

Abstract

An energy converter (1) comprising at least one electrochemical cell (3) and a member (5) forming a switch. The electrochemical cell comprises a chamber (31), two electrodes (33; 35), each being arranged at least in part in the chamber, and an electrolyte (37) contained in the chamber between the two electrodes. The composition and the structure of each of the two electrodes and of the electrolyte are selected conjointly in such a way that: - each of the electrodes is chemically inert in the electrolyte, and - in the absence of external polarisation, the electrodes have a non-zero difference in potential with respect to each other. The member forming a switch is electrically connected between the two electrodes. The member is arranged to switch alternately between an open state and a closed state by means of an external energy.

IPC Classes  ?

• H01G 11/04 - Hybrid capacitors
• H01G 11/08 - Structural combinations, e.g. assembly or connection, of hybrid or EDL capacitors with other electric components, at least one hybrid or EDL capacitor being the main component
• H01G 11/14 - Arrangements or processes for adjusting or protecting hybrid or EDL capacitors
• H01G 11/74 - Terminals, e.g. extensions of current collectors
• H01M 12/00 - Hybrid cellsManufacture thereof
• H01G 11/82 - Fixing or assembling a capacitive element in a housing, e.g. mounting electrodes, current collectors or terminals in containers or encapsulations

Abstract

The present application describes a process for the preparation of titanium-based compounds having an anatase type structure with cationic vacancies arising from a partial substitution of oxygen atoms by fluorine atoms and hydroxyl groups. Electrochemically active materials comprising the titanium-based compounds for use in lithium-ion battery electrodes are also described.

IPC Classes  ?

• H01M 4/485 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of mixed oxides or hydroxides for inserting or intercalating light metals, e.g. LiTi2O4 or LiTi2OxFy
• C30B 7/14 - Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions the crystallising materials being formed by chemical reactions in the solution
• C30B 29/16 - Oxides
• H01M 4/1315 - Electrodes based on mixed oxides or hydroxides, or on mixtures of oxides or hydroxides, e.g. LiCoOx containing halogen atoms, e.g. LiCoOxFy
• C30B 29/10 - Inorganic compounds or compositions
• C30B 29/60 - Single crystals or homogeneous polycrystalline material with defined structure characterised by the material or by their shape characterised by shape
• C01G 23/00 - Compounds of titanium
• C30B 29/64 - Flat crystals, e.g. plates, strips or discs
• H01M 10/0525 - Rocking-chair batteries, i.e. batteries with lithium insertion or intercalation in both electrodesLithium-ion batteries
• H01M 10/052 - Li-accumulators

Abstract

The present invention pertains to the field of nanoimprint lithography (NIL) processes and more specifically to a soft NIL process used for providing a sol-gel patterned layer on a substrate. Specifically, this process comprises a step of adjusting the solvent uptake of the sol- gel film to 10 to 50% vol., preferably between 15 and 40% vol., by varying the relative pressure of the solvent while a soft mould is applied onto the substrate coated with the sol-gel film.

IPC Classes  ?

• G03F 7/00 - Photomechanical, e.g. photolithographic, production of textured or patterned surfaces, e.g. printed surfacesMaterials therefor, e.g. comprising photoresistsApparatus specially adapted therefor

Abstract

The invention relates to a method for obtaining a numerical model, the numerical model associating at least one objective measurement to a subjective sensation, the method comprising the steps of: a) imaging the at least one area of the brain by using unfocused waves produced by a transcranial ultrasound probe (20), to obtain at least one acquired image of the activity of the area, b) evaluating a physical quantity representative of the activity of the at least one area based on the acquired images, to obtain at least one objective measurement, c) obtaining from the subject at least one numerical value representative of a subjective sensation, and d) determining the numerical model by using the obtained objective measurement and the obtained numerical value.

IPC Classes  ?

• G09B 23/28 - Models for scientific, medical, or mathematical purposes, e.g. full-sized device for demonstration purposes for medicine
• A61B 8/08 - Clinical applications
• A61B 8/00 - Diagnosis using ultrasonic, sonic or infrasonic waves
• G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
• A61B 8/06 - Measuring blood flow
• G06T 7/00 - Image analysis

Abstract

The present invention relates to methods and pharmaceutical compositions for preventing or treating inflammatory bowel diseases.

IPC Classes  ?

• A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis
• C12R 1/225 - Lactobacillus
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

The invention relates to a method for designing a flexible blade or an articulated rigid blade with one or more torsion springs, for a wind turbine or a water turbine, the flexible blade being designed to passively control the pitch angle of the wind turbine or of the water turbine during operation, the method comprising the following steps: a) receiving the known geometric profile; b) determining a change in the optimal pitch angle, 0o opt rigid, as a function of the specific speed λ; c) determining the local behaviour of the flexible blade or of the articulated blade and local ratios relating to the aerodynamic loading and to the centrifugal force being exerted on the blade; d) determining local values of the bending modulus B of the flexible blade/the stiffness of the torsion spring and of the mass density p of the blade; and e) providing information relating to the selection of the material.

IPC Classes  ?

• F03D 1/06 - Rotors

Abstract

The invention relates to a process for permanently electrostatically doping a layer of a conductive or non-conductive material that is deposited on a solid substrate, to the doped material obtained according to this process, and to the use of such a material.

IPC Classes  ?

• C03C 17/245 - Oxides by deposition from the vapour phase
• C03C 17/22 - Surface treatment of glass, e.g. of devitrified glass, not in the form of fibres or filaments, by coating with other inorganic material
• C03C 17/23 - Oxides
• H01L 31/18 - Processes or apparatus specially adapted for the manufacture or treatment of these devices or of parts thereof
• H01L 31/028 - Inorganic materials including, apart from doping material or other impurities, only elements of Group IV of the Periodic System
• H01L 31/032 - Inorganic materials including, apart from doping materials or other impurities, only compounds not provided for in groups
• H01L 31/0224 - Electrodes
• H01B 13/00 - Apparatus or processes specially adapted for manufacturing conductors or cables
• H01L 39/24 - Processes or apparatus specially adapted for the manufacture or treatment of devices provided for in group or of parts thereof

Abstract

Intraocular injection of adeno-associated viral (AAV) vectors has been an evident route for delivering gene drugs into the retina. Currently, the vectors need to be injected into the subretinal space in order to provide gene delivery to cones. In this approach, gene delivery is limited to cells that contact the local "bleb" of injected fluid. Furthermore, retinal detachment that occurs during subretinal injections is a concern in eyes with retinal degeneration. Here, the inventors establish several new vector-promoter combinations to overcome the limitations associated with AAV-mediated cone transduction in the fovea with supporting studies in mouse models, human induced pluripotent stem cell-derived organoids, post-mortem human retinal explants and living macaques. They show that an engineered AAV2 variant provides gene delivery to foveal cones with a well-tolerated dose administered intravitreally. The delivery modality relies on a cone-specific promoter and result in high-level transgene expression compatible with optogenetic vision restoration. Accordingly, the present invention relates to method of expressing a polynucleotide of interest in the cone photoreceptors of a subject comprising intravitreal delivery of a therapeutically effective amount of a recombinant AAV2-derived vector comprising a VP1 capsid protein as set forth in SEQ ID NO: 1 and the polynucleotide of interest under the control of the PR1.7 promoter as set forth in SEQ ID NO:2.

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• C07K 14/72 - ReceptorsCell surface antigensCell surface determinants for hormones
• C12N 15/86 - Viral vectors

Abstract

Disclosed is a fluidic device including at least: a) a solid matrix; b) a textile component, embedded in the matrix and mechanically cohesive with the matrix; c) at least one channel embedded in the matrix and entangled with the textile component, the channel being at least partly open. A method for making a fluidic device includes providing a textile component including support fibers and at least a movable fiber entangled with the textile, embedding at least part of the textile and part of the movable fiber, in a matrix precursor material, applying a treatment in order to obtain a solid matrix.

IPC Classes  ?

• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers
• B32B 7/00 - Layered products characterised by the relation between layers Layered products characterised by the relative orientation of features between layers, or by the relative values of a measurable parameter between layers, i.e. products comprising layers having different physical, chemical or physicochemical properties Layered products characterised by the interconnection of layers
• D03D 11/02 - Fabrics formed with pockets, tubes, loops, folds, tucks or flaps
• F16K 99/00 - Subject matter not provided for in other groups of this subclass
• D03D 15/06 - Woven fabrics characterised by the material or construction of the yarn or other warp or weft elements used using scaffolding threads, i.e. threads removed after weaving
• D06M 15/15 - Proteins or derivatives thereof
• D06M 15/643 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds containing silicon in the main chain
• F16L 11/08 - Hoses, i.e. flexible pipes made of rubber or flexible plastics with reinforcements embedded in the wall
• B29C 70/02 - Shaping composites, i.e. plastics material comprising reinforcements, fillers or preformed parts, e.g. inserts comprising combinations of reinforcements and fillers incorporated in matrix material, forming one or more layers, with or without non-reinforced or non-filled layers
• B29C 70/22 - Fibrous reinforcements only characterised by the structure of fibrous reinforcements using fibres of substantial or continuous length oriented in at least two directions forming a two dimensional structure
• D03D 13/00 - Woven fabrics characterised by the special disposition of the warp or weft threads, e.g. with curved weft threads, with discontinuous warp threads, with diagonal warp or weft
• B32B 5/02 - Layered products characterised by the non-homogeneity or physical structure of a layer characterised by structural features of a layer comprising fibres or filaments
• B32B 3/20 - Layered products comprising a layer with external or internal discontinuities or unevennesses, or a layer of non-planar shapeLayered products comprising a layer having particular features of form characterised by a discontinuous layer, i.e. apertured or formed of separate pieces of material characterised by an internal layer formed of separate pieces of material of hollow pieces, e.g. tubesLayered products comprising a layer with external or internal discontinuities or unevennesses, or a layer of non-planar shapeLayered products comprising a layer having particular features of form characterised by a discontinuous layer, i.e. apertured or formed of separate pieces of material characterised by an internal layer formed of separate pieces of material of pieces with channels or cavities
• B32B 5/26 - Layered products characterised by the non-homogeneity or physical structure of a layer characterised by the presence of two or more layers which comprise fibres, filaments, granules, or powder, or are foamed or specifically porous one layer being a fibrous or filamentary layer another layer also being fibrous or filamentary
• B32B 5/14 - Layered products characterised by the non-homogeneity or physical structure of a layer characterised by a layer differing constitutionally or physically in different parts, e.g. denser near its faces
• B32B 3/08 - Layered products comprising a layer with external or internal discontinuities or unevennesses, or a layer of non-planar shapeLayered products comprising a layer having particular features of form characterised by features of form at particular places, e.g. in edge regions characterised by added members at particular parts
• B32B 3/30 - Layered products comprising a layer with external or internal discontinuities or unevennesses, or a layer of non-planar shapeLayered products comprising a layer having particular features of form characterised by a particular shape of the outline of the cross-section of a continuous layerLayered products comprising a layer with external or internal discontinuities or unevennesses, or a layer of non-planar shapeLayered products comprising a layer having particular features of form characterised by a layer with cavities or internal voids characterised by a layer formed with recesses or projections, e.g. grooved, ribbed
• D06M 101/06 - Vegetal fibres cellulosic

Abstract

Disclosed is a minifluidic device including a matrix, an elongated guiding duct embedded at least in part in the matrix, with at least one port to the outside of the matrix, a movable fiber at least partly contained in the guiding duct, and able to undergo within the guiding duct, and at least along some part of the fiber, at least one action selected among a sliding, or a deformation, or a rotation and at least one of the movable fiber or the guiding duct is elastic or is non linear along at least part of its length, or at least part of the matrix is elastic.

IPC Classes  ?

• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers
• F16K 99/00 - Subject matter not provided for in other groups of this subclass

Abstract

The invention relates to a method and system for managing data exchanges in a communications network, comprising a centralised entity (20) that is provided, at least, with knowledge of the data exchange requirements between the terminals Mi (21) and their location in the network, in order to control the exchange of messages between the terminals.

IPC Classes  ?

• H04W 4/02 - Services making use of location information
• G06F 17/30 - Information retrieval; Database structures therefor
• H04W 76/00 - Connection management

Abstract

The invention relates to a control method for a multi-core processor comprising a plurality of cores (10) sharing at least one common material resource (12) according to a sharing policy based on different time windows (F), each time window (F) being attributed to at least one core (10). The control method comprises the anticipation of a request to be emitted by a software application (AP) run by a core (10) and requiring a transaction between said core (10) and the common resource (12), the planning of the transaction in a time window (F) to be attributed to said core (10) for access to the common resource (12), the implementation of the planned transaction and the loading of the data into a private cache memory (16) of said core (10), and the restitution of the data to the software application (AP) from the private cache memory (16).

IPC Classes  ?

• G06F 9/52 - Program synchronisationMutual exclusion, e.g. by means of semaphores

Abstract

The present invention relates to methods of predicting the survival time of patients suffering from CMS3 colorectal cancer. The inventors performed bivariate Cox models for analyzing the impact of stimulatory/Inhibitory immune checkpoint (ICK) expression on the survival of patients suffering from colorectal cancers (CMS1, CMS2, CMS3, CMS4, and MSI) in 2 cohorts (CIT and TCGA) or when the corhorts are combined. The inventors demonstrated that the expression of stimulatory ICK metagene was associated with good prognosis in CMS3. Thus, the present invention relates to a method of predicting the survival time of a patient suffering from a CMS3 colorectal cancer comprising i) determining the expression level of at least one immune stimulatory checkpoint molecule in a tumor tissue sample obtained from the patient, ii) comparing the expression level determined at step i) with a predetermined reference value and iii) concluding that the patient will have a long survival time when the level determined at step i) is higher than the predetermined reference value or concluding that the patient will have a short survival time when the level determined at step i) is lower than the predetermined reference value.

IPC Classes  ?

• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids

Abstract

The present invention relates to methods for predicting the survival time of patients suffering from a microsatellite stable colorectal cancer. The inventors performed bivariate Cox models for analyzing the impact of stimulatory/Inhibitory immune checkpoint (ICK) expression on the survival of patients suffering from colorectal cancers (CMS1, CMS2, CMS3, CMS4, and MSI) in 2 cohorts (CIT and TCGA) or when the corhorts are combined. The inventors demonstrated that the metagenes corresponding to ICKs, cytotoxic T-cell lymphocytes (CTL), cytotoxicity and Th1 orientation were overexpressed in MSS tumors belonging to CMS1 and CMS4 as compared to MSS CRC from CMS2 and CMS3 demonstrating their prognostic value. Thus, the invention relates to a method for predicting the survival time of a patient suffering from a microsatellite stable colorectal cancer belonging to consensus molecular subtypes CMS1 and CMS4 comprising i) determining the expression level of at least one gene encoding for an immune checkpoint protein in a tumor tissue sample obtained from the patient, ii) comparing the expression level determined at step i) with a predetermined reference value and iii) concluding that the patient will have a long survival time when the level determined at step i) is lower than the predetermined reference value or concluding that the patient will have a short survival time when the level determined at step i) is higher than the predetermined reference value.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids

Abstract

According to one aspect, the present description concerns a THz laser source (10) comprising a first generator (1) suitable for emitting at least a first light radiation (i) and a second light radiation (ii) having frequencies that are multiples of a first reference frequency; a second generator (2) suitable for emitting at least a first light radiation (iii) and a second light radiation (iv) having frequencies that are multiples of a second reference frequency different from the first reference frequency; the THz laser source also comprises a non-linear crystal (3) suitable for forming, from said first light radiations emitted by each of the first and second generators, a THz light radiation (v) generated by frequency difference, having frequency between 0.3 THz and 10 THz; and at least a first frequency stabilisation module for frequency stabilisation of one of said second radiations emitted by one of the first and second generators on an atomic transition.

IPC Classes  ?

• G02F 1/35 - Non-linear optics
• H01S 3/13 - Stabilisation of laser output parameters, e.g. frequency or amplitude
• H01S 3/00 - Lasers, i.e. devices using stimulated emission of electromagnetic radiation in the infrared, visible or ultraviolet wave range

Abstract

The invention relates to a sol-gel method for producing an anti-corrosion coating consisting of at least one layer (31, 32) of an oxide on a metal substrate (10). A non-aqueous solution (1) of a precursor of the oxide is prepared (SI) and deposited (S2) on one surface (11) at least of the metal substrate in order to cover said surface at least partially with a film (20) comprising the precursor of the oxide. Hydrolysis-condensation of the precursor of the oxide is carried out (S3) by exposing the film to a humid atmosphere in order to form an oxide network in the film. Then, a treatment for stabilising the film on the surface of the substrate is carried out (S4), followed by a heat treatment (S5) of the surface of the metal substrate in order to crystallise the network of oxide and form the anti-corrosion coating.

IPC Classes  ?

• C23C 18/12 - Chemical coating by decomposition of either liquid compounds or solutions of the coating forming compounds, without leaving reaction products of surface material in the coatingContact plating by thermal decomposition characterised by the deposition of inorganic material other than metallic material

Abstract

The invention relates to the use of HNRNPC-expressing vectors for preventing and/or treating a tauopathy, such as Alzheimer's disease. The invention relates to methods for detecting a risk of developing a tauopathy such Alzheimer's disease in a patient, comprising the step of detecting the level of HNRNPC in a biological sample obtained from said patient.

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Abstract

The sensory substitution system comprises a portable matrix of exciters (1) that can be worn by a user in such a way that the exciters (5) are placed against the skin of a user, as well as a control circuit (8) for the exciters of the matrix. An asynchronous signal source (10) provides the control circuit with an asynchronous signal representative of visual information organized according to a matrix of pixels. This asynchronous signal comprises, for each pixel, successive events associated in an asynchronous manner with said pixel.

IPC Classes  ?

• A61F 9/08 - Devices or methods enabling eye-patients to replace direct visual perception by another kind of perception
• G06K 9/62 - Methods or arrangements for recognition using electronic means
• G06K 9/46 - Extraction of features or characteristics of the image

Abstract

The present invention relates to a piezosensitive coating (12) for detecting impacts (121, 122, 123, 124) on a substrate (10), comprising a matrix in which at least one piezochromic pigment is dispersed, said matrix being a hybrid sol-gel/polymer matrix composed of at least one organic precursor and one inorganic precursor that are polymerised, the piezochromic pigment being selected such that said coating changes colour as from a predetermined pressure threshold that corresponds to a transition pressure at which the piezochromic pigment in the matrix changes between two polymorphic forms of different colours. The invention further relates to a method for producing- such a piezosensitive coating.

IPC Classes  ?

• C09D 5/00 - Coating compositions, e.g. paints, varnishes or lacquers, characterised by their physical nature or the effects producedFilling pastes
• C09K 9/00 - Tenebrescent materials, i.e. materials for which the range of wavelengths for energy absorption is changed as a result of excitation by some form of energy
• C08K 3/22 - OxidesHydroxides of metals
• C09D 7/61 - Additives non-macromolecular inorganic

Abstract

The present invention relates to the synergistic combination of the short and long Rod-Derived Cone Viability Factors and to methods for treating retinal degenerative diseases.

IPC Classes  ?

• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61P 27/02 - Ophthalmic agents
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• C12N 15/86 - Viral vectors
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy

Abstract

Device (100) for holding in position a probe for placing the inside of a patient's body in communication with the outside, characterized in that it comprises, arranged along a longitudinal axis (X-X′) of the device: at its distal end, a means (110) of supporting the device on the patient's body and that extends radially, comprising an axial opening (114) for the passage of said probe and comprising a first radial opening (111) communicating with the said axial opening, at its proximal end, a means (120) of guiding said probe comprising a second radial opening (121), a means (130) of spacing said bearing means and said guide means apart longitudinally.

IPC Classes  ?

• A61M 25/02 - Holding devices, e.g. on the body
• A61M 16/04 - Tracheal tubes

Abstract

The invention relates to an allele specific siRNA able to silence the expression of only one allele of a heterozygous DNM2 gene, for treating diseases caused by heterozygous mutation and/or overexpression of Dynamin 2.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 31/713 - Double-stranded nucleic acids or oligonucleotides

Abstract

The present invention relates to methods and pharmaceutical compositions for the treatment of retinal degenerative diseases. The inventors identified a new key actor of the mechanism underlying the protective role of RdCVF: 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 2 (PFKFB2). The inventors showed that PFKFB2 is expressed by cones in a rod-dependant manner. In particular, they showed that its expression follows the viability of cones: its expression is lost in an animal model retinitis pigmentosa. The inventors accumulated evidences that PFKFB2, especially its kinase domain, is involved in the mechanism of action of RdCVF. More particularly they showed that transduction of a polynucleotide encoding for PFKFB2 increases cone survival. In particular, the present invention relates to a method of treating a retinal degenerative disease in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a polynucleotide encoding for the PFKFB2 kinase domain.

IPC Classes  ?

• A61K 38/45 - Transferases (2)
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• C12N 15/861 - Adenoviral vectors
• A61P 27/02 - Ophthalmic agents

Abstract

2 powders, of nanometric or micrometric size.

IPC Classes  ?

• C01B 25/08 - Other phosphides
• C01B 35/10 - Compounds containing boron and oxygen

Abstract

Method implemented by computer for simulating an optical system (102) comprising the steps consisting in: a) defining a set of light rays or beams at the input (e) of the optical system, each said light ray or beam being represented by a first vector of parameters (101, x e ); and b) calculating, for each said light ray or beam at the input of the optical system, a light ray or beams at the output (s) of the optical system, represented by a second vector of parameters (103, xs) by applying, to each said light ray or beam at the input of the optical system, one and the same nonlinear function, termed the transmission function (I), representative of the optical system as a whole. Computer program product for the implementation of such a method.

IPC Classes  ?

• G06F 17/18 - Complex mathematical operations for evaluating statistical data
• G02C 7/02 - LensesLens systems

Abstract

The present invention concerns the isolation, purification and characterisation of a protein having a novel enzymatic activity, i.e. an alpha-1,3-(3,6-anhydro)-D-galactosidase activity. This protein can be used for hydrolysing polysaccharides and oligosaccharides containing (non-sulfated) beta-carrabiose units, which may be present naturally (e.g. carrageenans extracted from red seaweeds of the Tichocarpus and Furcellaria genus) or introduced artificially by chemical or enzymatic desulfation (for example from kappa- and iota-carrageenans). The activity of this protein, demonstrated on oligo-carrageenans with a hybrid kappa/beta structure, makes it possible, for example, to produce the 3,6-anhydro-D-galactose monosaccharide and odd-numbered oligo-carrageenans of a defined size of the carrabiose series, i.e. having a D-galactose residue at the non-reducing end.

IPC Classes  ?

• A01H 13/00 - Algae
• A61K 8/73 - Polysaccharides
• A61K 31/731 - Carrageenans
• C08B 37/00 - Preparation of polysaccharides not provided for in groups Derivatives thereof
• C12N 9/24 - Hydrolases (3.) acting on glycosyl compounds (3.2)

Abstract

The invention relates to a portable device (1) for estimating at least one characteristic parameter of a polymer, characterized in that the device includes: at least one infrared source (101), each infrared source (101) being able to emit, toward the polymer, a spectral line, representing a maximum emission energy, of wavelength chosen from 10 μm, 9.5 μm, 7.2 μm, 6 μm, 3.5 μm and 2.7 μm, or of wave number chosen from 1000 cm-1, 1050 cm-1, 1350 cm-1, 1700 cm-1, 2900 cm-1 and 3700 cm-1; at least one infrared detector (102) that is able to receive the infrared radiation (112) reflected by the polymer (M) in response to the spectral line; and a unit for determining the characteristic parameter of the polymer (M) depending on the energy present in said spectral line in the infrared radiation (112) reflected by the polymer (M) and received by the infrared detector (102).

IPC Classes  ?

• G01N 21/3563 - Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light for analysing solidsPreparation of samples therefor
• G01N 21/55 - Specular reflectivity
• G01N 21/84 - Systems specially adapted for particular applications

Abstract

The present invention relates to a process for characterizing a blood sample, comprising: insertion, into a channel, of a solution comprising blood platelets, said channel comprising an inlet and an outlet, the solution being inserted via the inlet of the channel; creating a pressure difference between the inlet and the outlet of the channel so as to cause the solution to progress from the inlet towards the outlet of the channel; passage of the solution into a measurement zone of the channel, provided with electrodes; measurement, by said electrodes and measurement means, of an electric signal while said electrodes are covered by the solution in the channel, characterized in that the progression of the solution from the inlet towards the outlet of the channel comprises a progression of a front between, on the one hand, the solution extending from the front towards the inlet of the channel and, on the other hand, a gas extending from the front towards the outlet of the channel.

IPC Classes  ?

• G01N 33/49 - Physical analysis of biological material of liquid biological material blood

Abstract

The invention relates to a bioreactor comprising a tank containing a culture medium in which a cell culture composed of algae cells is dispersed. The cell culture of algae has a concentration greater than 0.1 g/L in the culture medium, and each algal cell has a minimum absorption in a specific range of wavelengths of light. The bioreactor comprises a light source that is capable of emitting incident light in the direction of the tank, 60% of the photons of the incident light having a wavelength which is included in said specific range of wavelengths of light. The invention also relates to the use of the bioreactor for the production of biomass.

IPC Classes  ?

• C12M 1/00 - Apparatus for enzymology or microbiology

Abstract

The present invention relates to a compound of the following general formula (I); or a pharmaceutically acceptable salt and/or solvate thereof, for use as drug, particularly intended for inhibiting a programmed cell death route selected from the group consisting of ferroptosis, oxytosis and cellular necroptosis. The present invention also relates to a compound of general formula (I) for use as a drug for neuroprotection as well as for preventing and/or treating disorders associated with cellular necroptosis or ferroptosis. The present invention also relates to a pharmaceutical composition comprising a compound of general formula (I), or a pharmaceutically acceptable salt and/or solvate thereof. The present invention also encompasses the use of a compound of the general formula (I)for organs preservation.

IPC Classes  ?

• C07D 311/20 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 hydrogenated in the hetero ring
• C07D 311/54 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms in positions 2 and 4 with one hydrogen atom in position 3 substituted in the carbocyclic ring
• A61K 31/353 - 3,4-Dihydrobenzopyrans, e.g. chroman, catechin

Abstract

The invention relates to a piezoelectric transducer of the type comprising a stack of a contact part (1), of a piezoelectric chip (2) and of a holder (3) of very high stiffness. Specifically, the contact part (1) forms tips, the respective apex of which forms points of contact that are spatially isolated from one another. The invention also relates to a process for manufacturing such a contact part and to a resonant ultrasound spectroscopy device comprising one or more piezoelectric transducers according to the invention.

IPC Classes  ?

• G01N 29/036 - Analysing fluids by measuring frequency or resonance of acoustic waves
• G01H 13/00 - Measuring resonant frequency
• G01N 29/04 - Analysing solids
• G01N 29/22 - Investigating or analysing materials by the use of ultrasonic, sonic or infrasonic wavesVisualisation of the interior of objects by transmitting ultrasonic or sonic waves through the object Details
• G01N 29/24 - Probes
• G01N 29/28 - Investigating or analysing materials by the use of ultrasonic, sonic or infrasonic wavesVisualisation of the interior of objects by transmitting ultrasonic or sonic waves through the object Details providing acoustic coupling
• G10K 11/24 - Methods or devices for transmitting, conducting or directing sound for conducting sound through solid bodies, e.g. wires

Abstract

The invention relates to a supercapacitor comprising: an electrolyte having a first end and a second end opposite the first end; a first electrode (E1) in contact with the first end of the electrolyte; and a second electrode (E2) in contact with the second end of the electrolyte. In particular, the electrolyte is made from an ionically conductive and electronically insulating solid material (D).

IPC Classes  ?

• G11C 13/00 - Digital stores characterised by the use of storage elements not covered by groups , , or
• H01L 45/00 - Solid state devices specially adapted for rectifying, amplifying, oscillating, or switching without a potential-jump barrier or surface barrier, e.g. dielectric triodes; Ovshinsky-effect devices; Processes or apparatus specially adapted for the manufacture or treatment thereof or of parts thereof
• H01G 11/56 - Solid electrolytes, e.g. gelsAdditives therein
• H01G 11/84 - Processes for the manufacture of hybrid or EDL capacitors, or components thereof
• H01G 11/14 - Arrangements or processes for adjusting or protecting hybrid or EDL capacitors
• G11C 13/02 - Digital stores characterised by the use of storage elements not covered by groups , , or using elements whose operation depends upon chemical change
• C04B 35/465 - Shaped ceramic products characterised by their compositionCeramic compositionsProcessing powders of inorganic compounds preparatory to the manufacturing of ceramic products based on oxides based on titanium oxides or titanates based on titanates based on alkaline earth metal titanates

Abstract

The present invention aims at improving the Doppler imaging of a biological sample comprising blood. For this, it is proposed a method for imaging a biological sample (10), the sample (10) comprising blood (14) comprising diffusors and solid tissue (16), the method comprising obtaining observation, each observation being characterized by a different point spread function associating a signal to each location of the region of interest, the signal comprising a first contribution representative of the diffusors of blood vessels within the location, a second contribution representative of the tissue diffusors and a third contribution representative of blood signal associated to blood diffusors outside of the location, and estimating, for each location, the blood flow by using a statistical analysis.

IPC Classes  ?

• A61B 8/06 - Measuring blood flow
• A61B 8/00 - Diagnosis using ultrasonic, sonic or infrasonic waves
• G01S 15/89 - Sonar systems specially adapted for specific applications for mapping or imaging
• A61B 8/08 - Clinical applications

Abstract

By analyzing the kinetics of the immunological parameters evocating the immune risk phenotype (IRP) in elderly subjects suffering from an acute event, the inventors have surprisingly identified that neopterin expressed highly in the subjects who has a short survival time after an acute event. Accordingly, the invention relates to a method for predicting the survival time in a subject suffering from an acute event comprising the following steps: i) determining neopterin level in a biological sample obtained from said subject; ii) comparing said level with its predetermined reference value and iii) concluding that the subject will have a short survival time when the level of neopterin is higher than its predetermined reference value or concluding that the subject will have a long survival time when the level of neopterin is lower than its predetermined reference value.

IPC Classes  ?

• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor

Abstract

The present invention relates to variants of acid-alpha glucosidase and uses thereof. Said variants are sequence-optimized and/or are linked to a heterogenous signal peptide.

IPC Classes  ?

• C12N 9/26 - Hydrolases (3.) acting on glycosyl compounds (3.2) acting on alpha-1, 4-glucosidic bonds, e.g. hyaluronidase, invertase, amylase

Abstract

The present invention relates to variants of acid-alpha glucosidase and uses thereof.

IPC Classes  ?

• C07K 16/44 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere

Abstract

Disclosed is the preparation of injectable collagen suspensions, to the method for preparing the suspensions, and to the uses thereof, particularly for forming dense collagen matrices.

IPC Classes  ?

• A61L 27/24 - Collagen
• A61L 27/50 - Materials characterised by their function or physical properties
• A61L 27/54 - Biologically active materials, e.g. therapeutic substances
• A61L 27/52 - Hydrogels or hydrocolloids
• A61K 8/02 - Cosmetics or similar toiletry preparations characterised by special physical form
• A61K 8/14 - Liposomes
• A61K 38/39 - Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
• A61K 8/65 - CollagenGelatinKeratinDerivatives or degradation products thereof
• A61Q 19/08 - Anti-ageing preparations
• A61K 8/60 - SugarsDerivatives thereof
• C08J 3/12 - Powdering or granulating

Abstract

An autonomous vehicle having a chassis and supporting legs, each of said legs being composed of at least two segments, an upper segment connected to the chassis via a first pivot, and a lower segment carrying a wheel at its lower end and connected to the upper segment by a second pivot; in addition, the lower segment is connected, via two opposing springs, to a pulley rigidly secured to the chassis in order to generate an angular rigidity about an equilibrium position corresponding to an upright orientation of the lower segment; and the upper segment is connected via two other opposing springs, at said first pivot, to a motorised pulley rigidly secured to the chassis and suitable for controlling the moment exerted on the upper segment about a nominal position corresponding to a horizontal orientation of the upper segment, this moment control being determined on the basis of a measurement of a first angle formed by the upper segment relative to its nominal position, a measurement of a second angle formed by the lower segment relative to its equilibrium position, and the trim of the chassis.

IPC Classes  ?

• B60K 17/32 - Arrangement or mounting of transmissions in vehicles the ultimate propulsive elements, e.g. ground wheels, being rockable about a horizontal pivot

Abstract

An interstitial ultrasound thermal ablation applicator for conformal treatment of an inhomogeneous tumor lesion includes: a body having a longitudinal axis; and a plurality of array transducers mounted on the body, arranged side by side and having azimuth directions parallel to the longitudinal axis of the body, and having outer faces disposed in a polygonal arrangement; the plurality of array transducers having predetermined elevation dimensions defined for directing emitted ultrasonic energy to obtain a conformal volume treatment of the tumor lesions. An electronic driving method for driving an applicator having multiple independent transducer elements arranged in rows and columns includes: controlling focal parameters of each row and column of transducer elements; and controlling a contribution of each row and column of transducer elements in a manner to provide a conformal ablated volume.

IPC Classes  ?

• A61N 7/02 - Localised ultrasound hyperthermia
• A61N 7/00 - Ultrasound therapy

Abstract

The present invention relates to methods for quantifying the population of myeloid dendritic cells in a tissue sample. The tumor microenvironment is a complex tissue which contains many distinct cell populations, and whose composition may predict prognosis and response to therapies. In the present disclosure, using samples of purified cell populations, the inventors defined specific and robust transcriptomic markers of the immune and stromal cell populations of the tumor microenvironment, and they quantitatively validated them in an in-vitro RNA mixture model. More, they developed the 'Microenvironment Cell Populations-counter' (MCP-counter) method, which, using transcriptomic data, allows a robust quantification of the abundance of immune and stromal populations in cellularly heterogeneous healthy and cancerous tissues. Thus, the present invention relates to a method for quantifying the population of myeloid dendritic cells in a tissue sample obtained from a subject comprising determining the expression level of at least one gene selected from the group consisting of CD1E, CLEC10A, CLIC2, CD1A, WFDC21P and CD1B.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids

Abstract

The present invention relates to a method for routing a plurality of data streams in a wireless communication network (R) comprising a plurality of nodes connected by wireless communication links, the method comprising the steps of: identifying (101) at least one group of wireless communication links of the network which would all interfere with each other if they were used simultaneously to transmit data, determining (102), for each data stream, a path in the network for transmitting the data stream, each path being characterised by a set of nodes of the network, the determination comprising solving a system of equations of which the paths are solutions, the system of equations defining the following rules: the total number of nodes to include in the paths is to be minimised; for each identified group, the rate of use in capacity of the group, by the plurality of data streams, must be less than or equal to a predetermined threshold; each stream is to be transmitted from a predetermined source node of the network to a predetermined recipient node of the network; each node not being a recipient and receiving a stream must retransmit this stream to a single other node; the method further comprising a deactivation (103) of at least one node of the network which is not included in at least one of the determined paths.

IPC Classes  ?

• H04L 12/729 - Selecting a path with suitable bandwidth or throughput
• H04W 40/16 - Communication route or path selection, e.g. power-based or shortest path routing based on transmission quality or channel quality based on interference
• H04L 12/721 - Routing procedures, e.g. shortest path routing, source routing, link state routing or distance vector routing

Abstract

The present invention relates to compounds of the following general formula (I) or (II) or a pharmaceutically acceptable salt and/or solvate thereof, for use in the prevention and/or the treatment of disorders associated to gammaherpesvirinae, in particular to the human herpesvirus 8 (HHV8) or the human herpes virus 4 (HHV4), and pharmaceutical compositions containing such compounds.

IPC Classes  ?

• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61K 31/382 - Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
• A61K 31/4706 - 4-Aminoquinolines8-Aminoquinolines, e.g. chloroquine, primaquine
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 31/12 - Antivirals
• A61P 31/22 - Antivirals for DNA viruses for herpes viruses

Abstract

The invention relates to a device (3) for detecting a blood alcohol level, comprising: - a flexible strip (1) intended to be exposed to an atmosphere to be tested (4), particularly one optionally filled with ethanol and more particularly with a person's exhaled breath, the flexible strip (1) comprising a flexible substrate (5) and a hydrophobic porous layer (7) arranged on the flexible substrate (5) and having a surface area of accessible pores of the porous layer (7) arranged on the flexible substrate (5) greater than 140cm2/cm2, the flexible substrate (5) being prestressed so that, in the absence of ethanol, the flexible strip (1) has an initial curvature and in the presence of ethanol the flexible strip (1) has a lower curvature, - a detector (21) of variation of the curvature of the flexible strip (1) and - a processing and calculating unit (23) configured for deducing, from the measured variation of the curvature of the flexible strip (1), a parameter corresponding to a blood alcohol level.

IPC Classes  ?

• G01N 33/497 - Physical analysis of biological material of gaseous biological material, e.g. breath

Abstract

The invention relates to a pumped-down optical apparatus (1) including a vacuum chamber (2), the vacuum chamber including walls bounding a sealably closed interior space (5), wherein an internal surface of the walls (3, 4) includes a layer of oxidized metal alloy, the metal alloy including at least one metal chosen from the list consisting of: titanium, copper, steel and aluminium, the pumped-down optical apparatus furthermore including a porthole able to transmit a laser beam (10, 11) emitted by an optical source (7, 8) at a wavelength of the optical source, the oxidized metal alloy being able to absorb the wavelength of the optical source (7, 8) so that the total reflectivity of the internal surface of the wall (3, 4) is lower than 0.5 for the wavelength of the optical source. The invention also relates to a method for obtaining the pumped-down optical apparatus.

IPC Classes  ?

• G01C 19/64 - Gyrometers using the Sagnac effect, i.e. rotation-induced shifts between counter-rotating electromagnetic beams
• B01J 3/03 - Pressure vessels, or vacuum vessels, having closure members or seals specially adapted therefor
• H01L 21/67 - Apparatus specially adapted for handling semiconductor or electric solid state devices during manufacture or treatment thereofApparatus specially adapted for handling wafers during manufacture or treatment of semiconductor or electric solid state devices or components
• G01V 7/00 - Measuring gravitational fields or wavesGravimetric prospecting or detecting
• G04F 5/14 - Apparatus for producing preselected time intervals for use as timing standards using atomic clocks
• B01J 3/00 - Processes of utilising sub-atmospheric or super-atmospheric pressure to effect chemical or physical change of matterApparatus therefor
• C23C 8/10 - Oxidising

Abstract

The present invention relates to an electrode comprising an electrically conductive substrate of which at least one portion of the surface is covered with a metal deposit of copper, the surface of said deposit being in an oxidised, sulphurised, selenised and/or tellurised form and the deposit having a specific surface area of more than 1 m2/g; a method for preparing such an electrode; and a method for oxygenising water with dioxygen involving such an electrode.

IPC Classes  ?

• C25B 11/04 - ElectrodesManufacture thereof not otherwise provided for characterised by the material
• C25B 1/04 - Hydrogen or oxygen by electrolysis of water
• C25D 7/00 - Electroplating characterised by the article coated
• H01M 4/88 - Processes of manufacture

Abstract

The invention relates to a new method for the prevention and treatment of wave burst arrhythmia by administering a gestagen having an androgenic effect.

IPC Classes  ?

• A61K 31/568 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstane, testosterone
• A61K 31/5685 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstane, testosterone having an oxo group in position 17, e.g. androsterone
• A61K 31/56 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• A61K 31/57 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
• A61K 31/565 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol
• A61K 31/567 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone

Abstract

A method and a device allow optical properties of a sample to be estimated. The method includes the illumination of the sample by a first light source, and the formation of an image of the sample thus illuminated, on the basis of which a first optical property is estimated, at various points on a surface of the sample. The method also includes measuring an auxiliary optical property of the sample and estimating the first optical property, taking account of the auxiliary optical property measured on the sample.

IPC Classes  ?

• G01N 21/55 - Specular reflectivity
• G01N 21/47 - Scattering, i.e. diffuse reflection
• G01N 33/483 - Physical analysis of biological material

Abstract

The present invention relates to the field of cardiology and, more specifically, to a novel algorithm that can be used, in particular, in a method for determining if a drug is likely to induce a cardiac ventricular repolarisation disturbance, based on variations in electrocardiogram data.

IPC Classes  ?

• G06F 19/00 - Digital computing or data processing equipment or methods, specially adapted for specific applications (specially adapted for specific functions G06F 17/00;data processing systems or methods specially adapted for administrative, commercial, financial, managerial, supervisory or forecasting purposes G06Q;healthcare informatics G16H)
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/04 - Measuring bioelectric signals of the body or parts thereof
• G06K 9/00 - Methods or arrangements for reading or recognising printed or written characters or for recognising patterns, e.g. fingerprints

Abstract

The present invention relates to a method for transiently disrupting a region of the blood-brain barrier (BBB) of a human using ultrasounds in the presence of an ultrasound contrast agent, and uses thereof. The method comprises the application of at least one ultrasound (US) beam with a pressure level higher than 1 MPa and a resonance frequency ranging from 0.5 to 1.5 MHz.

IPC Classes  ?

• A61N 7/00 - Ultrasound therapy
• A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
• A61K 31/555 - Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
• A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine

Goods & Services

Software for making medical diagnoses, developing treatment plans, monitoring, checking and simulating patient care, managing and transmitting patient data, information and digital images and testing medical apparatus; search software (recorded programs) in the field of medical imaging; software (recorded programs) for recording, storing, analyzing, transmitting, generating, displaying and processing medical data, medical images, signals (biological, physiological, physical, positional and audio); surgery monitoring software (recorded programs); medical and surgery management software (recorded programs); software for recording, storing, analyzing, transmitting, operating, managing and processing medical data; tools (software and recorded programs) for developing software for recording, storing, analyzing, transmitting, generating, displaying and processing medical data, medical images, signals (biological, physiological, physical, positional and audio); apparatus for recording, storing, analyzing, transmitting, generating, displaying and processing medical data, medical images, signals (biological, physiological, physical, positional and audio); scientific, optical and medical checking (supervision) apparatus and instruments; apparatus and equipment for recording, transmitting, reproducing medical images and/or sound; apparatus and equipment for processing data, computers and computer peripherals for use in medical imaging; scientific instruments and application software in the field of medicine and biology to assist with prevention, diagnostics and therapy; image processing apparatus for medical imaging and visualization and related displays. Installation, maintenance and repair of software, equipment and computer systems and medical systems and apparatus. Design and development of computer systems for scientific and medical imaging and medical data management; technical project studies in the field of medical data and surgical and medical imaging; new product development and research for others in the field of medical imaging, visualization and medical data management; new product development and research for others with respect to recording, storing, analyzing, transmitting, generating, displaying and processing medical data, medical images, signals (biological, physiological, physical, positional and audio); design of computer systems to enable the simulation of physiological systems based on computer models using biomedical images and other signals; analyses, evaluations, appraisals and research in scientific and technological fields carried out by engineers; development, design, installation, maintenance, updating or rental of medical imaging and medical data mining software; computer programming, consultancy relating to computers and medical imaging and medical data mining software; technical support (consulting) relating to medical imaging and medical data mining software; conversion of data and computer programs (other than physical conversion) relating to medical imaging and medical data mining; conversion of data or documents from physical to electronic media relating to medical imaging and medical data mining; scientific research for medical purposes; expert activities relating to medical imaging and medical data mining carried out by engineers; engineering services relating to medical imaging and medical data mining; scientific studies and research relating to medical imaging and medical data mining; scientific studies and research on recording, storing, analyzing, transmitting, generating, displaying and processing medical data, medical images, signals (biological, physiological, physical, positional and audio); consultancy, studies and research relating to surgery, biology, chemistry, radiology, medical imaging; duplication of computer programs relating to medical imaging and medical data mining.

Abstract

The invention concerns a hydrated titanium oxyhydroxide compound, a composite material comprising same and an electrode and a catalyst comprising said hydrated titanium oxyhydroxide compound and said composite material. The invention also concerns a battery, in particular a lithium battery, comprising said electrode. It further concerns a method for producing said hydrated titanium oxyhydroxide compound and said composite material. The hydrated titanium oxyhydroxide compound according to the invention has the following formula I; TiOx(OH)y, nH2O Formula 1 in which: - 1.15 ≤ x ≤ 1.55, and 0.9 ≤ y ≤ 1.70, and 0.1 ≤ n ≤ 1, preferably 0.3 ≤ n ≤ 0.5, and most preferably n = 0.41, and the compound has an ordered lepidocrocite local structure over a distance of up to 1 nm inclusive, as determined by analysis of the pair-distribution function (PDF) obtained by synchrotron diffraction, but has a disordered structure over a distance of more than 1 nm, revealed by X-ray diffraction. The invention is applicable in the field of energy storage and supply, in particular.

IPC Classes  ?

• B01J 21/06 - Silicon, titanium, zirconium or hafniumOxides or hydroxides thereof
• C01G 23/04 - OxidesHydroxides
• C01G 23/053 - Producing by wet processes, e.g. hydrolysing titanium salts
• H01M 4/485 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of mixed oxides or hydroxides for inserting or intercalating light metals, e.g. LiTi2O4 or LiTi2OxFy

Abstract

The present invention concerns, in particular, a method for producing a catalyst intended to be incorporated into a catalytic converter system that can be used for treating an exhaust gas from a vehicle engine, said method comprising at least the following step: treating, by means of a gas phase, a structure comprising at least one zeolite, palladium and cerium, in order to obtain the catalyst, the gas phase comprising water vapour at a volume content of between 5% and 20% and a temperature of between 450 °C and 550 °C being imposed during said treatment.

IPC Classes  ?

• B01J 37/10 - Heat treatment in the presence of water, e.g. steam
• B01J 29/22 - Noble metals
• B01J 29/18 - Crystalline aluminosilicate zeolitesIsomorphous compounds thereof of the mordenite type
• B01D 53/94 - Chemical or biological purification of waste gases of engine exhaust gases by catalytic processes
• F01N 3/28 - Construction of catalytic reactors
• F01N 3/20 - Exhaust or silencing apparatus having means for purifying, rendering innocuous, or otherwise treating exhaust for rendering innocuous by thermal or catalytic conversion of noxious components of exhaust characterised by methods of operationControl specially adapted for catalytic conversion

Abstract

The invention concerns a method for managing a squad of mobile robotic vehicles, such as drones, each mobile robotic vehicle being configured to communicate and exchange information with other mobile robotic vehicles so that they constitute a network of mobile robotic vehicles and configured to communicate and exchange information with an operating center, said method comprising the following steps of: launching (Sl) a first mobile robotic vehicle (NO) which is the leader of the squad, the leader being configured to stay at a distance from an operating center (OC) for exchanging information with the operating center (OC) by ensuring that a quality of link (Q NO, OC ) of power exchanged between said first mobile robotic vehicle (NO) and said operating center (OC) is greater or equal to X dBm, the method comprising, if the quality of link (Q No - oc ) becomes lower than X dBm, launching (S4, S7) consecutively at least one mobile robotic vehicle (N1, N2,..., Nx) so that: each mobile robotic vehicle is configured to stay at distance from his closest neighbor(s) for exchanging information with his closest neighbor(s) by ensuring that a quality of link of power exchanged between said each mobile robotic vehicle and said closest neighbor(s) is greater or equal to X dBm; the last launched mobile robotic vehicle (Nx) is configured to stay at a distance from the operating center for exchanging information with the operating center by ensuring that a quality of link of power exchanged between said last mobile robotic vehicle and said operating center is greater or equal to X dBm.

IPC Classes  ?

• G05D 1/10 - Simultaneous control of position or course in three dimensions
• H04L 12/26 - Monitoring arrangements; Testing arrangements
• H04L 12/751 - Topology update or discovery
• H04L 12/24 - Arrangements for maintenance or administration

Abstract

The invention relates to ambient-temperature ferromagnetic cobalt nanoparticles, the production method thereof, a suspension of the nanoparticles, and the uses of said nanoparticles and said suspension, particularly in the field of high-density magnetic recording.

IPC Classes  ?

• B22F 1/00 - Metallic powderTreatment of metallic powder, e.g. to facilitate working or to improve properties
• B22F 9/24 - Making metallic powder or suspensions thereofApparatus or devices specially adapted therefor using chemical processes with reduction of metal compounds starting from liquid metal compounds, e.g. solutions

Abstract

The invention relates to the field of immunology and cell therapy. The invention relates to an in vitro or ex vivo method for obtaining hematopoietic cell population containing regulatory T cells (Tregs) specific for an irrelevant antigen, to a hematopoietic cell population obtained by said method, to a pharmaceutical composition and a product containing said hematopoietic cell population and therapeutic use thereof.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells

Abstract

The present invention relates to a nucleic acid sequence derived from the regulatory region of the human gamma-synuclein gene and having a promoter activity in retinal ganglion cells. The present invention also relates to expression cassettes or vectors comprising said promoter operably linked to a nucleic acid sequence encoding a polypeptide of interest as well as viral particles or host cells comprising said expression cassette or vector. The present invention also relates to the use of said expression cassettes, vectors, viral particles or cells in the treatment of ocular disease, in particular ocular disease associated with retinal ganglion cell or photoreceptor cell degeneration.

IPC Classes  ?

• C12N 15/861 - Adenoviral vectors

Abstract

The invention relates to a method for the treatment of amyotrophic lateral sclerosis (ALS). Specifically, the invention implements the use of an antisense sequence adapted to affect alternative splicing in a human SOD1 pre-mRNA, thereby leading to the destruction of the skipped m RNA by the cell machinery.

IPC Classes  ?

• C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
• C07H 21/02 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
• C12N 15/86 - Viral vectors

Abstract

The present invention relates to methods and compositions for the prevention or treatment of neurodegenerative diseases.

IPC Classes  ?

• A61K 38/00 - Medicinal preparations containing peptides
• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
• A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof

Abstract

The invention relates to a method and to a corresponding device for determining the slowness of propagation in a mode of propagation of an acoustic wave, including the following steps: a) transmitting an acoustic wave (OS) in a medium (M) using an acoustic source (SS); b) providing, with each sensor Tk of a set of n sensors (Tk, 1≤ k ≤ n, where n is an integer), the positions of which relative to one another and to the acoustic source are known, a transduction signal xk(t) that is dependent on the response time to the transmitted acoustic wave; c) carrying out, for slowness values s, a time shift τk(s) specific to each signal xk, i.e. xk(t+τk),k(t+τk), in order to reset in time said signals relative to each other; d) calculating interferometric signals C(t,s) on the basis of an estimator C which is a function of the quantity (I) or of the conjugate of said quantity, with xk = xk(t+τk) being a signal reset in time and x*k+j the conjugate of the signal xk+j = xk+j(t+τk+j); e) determining the slowness s0 of said propagation mode of the acoustic wave with one interferometric signal C(t,s) from the set of previously calculated interferometric signals C(t,s), said signal C(t,s) being selected on the basis of its complex argument and of its modulus.

IPC Classes  ?

• G01V 1/48 - Processing data

Abstract

The present invention relates to a method for determining the presence or risk of developing thrombosis or the risk of a bleeding event in a patient, which method comprises determining presence or concentration of PDGFB in a biological sample of the patient, in a biological sample of the patient.

IPC Classes  ?

• G01N 33/86 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving blood coagulating time

Abstract

The present invention relates to a microfluidic device to manipulate, select, treat, or cultivate living bodies, comprising a first chamber, a second chamber and a network of guiding tracks, wherein: said network of guiding tracks comprises at least one first guiding track connecting the first chamber and the second chamber and at least one second guiding track connecting said at least one first guiding track with at least two interconnections; and said at least one second guiding track comprises a curved part; said curved part exhibiting a concavity facing the second chamber or the part of the network connected to the second chamber.

IPC Classes  ?

• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers

Abstract

The present invention relates to methods and pharmaceutical compositions for the treatment of Alzheimer's disease. In particular, the present invention relates to a method of treating Alzheimer's disease in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a recombinant adeno-associated viral (AAV) vector comprising a polynucleotide encoding for an interleukin 2 (IL-2) polypeptide.

IPC Classes  ?

• A61K 38/20 - Interleukins
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• C12N 15/86 - Viral vectors

Abstract

The present invention relates to methods for quantifying the population of B cells in a tissue sample. In particular, the present invention relates to a method for quantifying the population of B cells in a tissue sample obtained from a subject comprising determining the expression level of at least one gene selected from the group consisting of MS4A1, CD19, CD79A, FCRL2, CR2, PAX5, CD22, BANK1 and IGKC.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids

Abstract

The present invention relates to methods for quantifying the population of cytotoxic lymphocytes in a tissue sample. In particular, the present invention relates to a method for quantifying the population of cytotoxic lymphocytes in a tissue sample obtained from a subject comprising determining the expression level of at least one gene selected from the group consisting of KLRC4-KLRK1 /// KLRK1, CD8A, KLRD1, GNLY, EOMES, KLRC3, KLRC4, FGFBP2 and KLRC1 /// KLRC2.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids

Abstract

The present invention relates to methods for quantifying the population of neutrophils in a tissue sample. In particular, the present invention relates to a method for quantifying the population of neutrophils in a tissue sample obtained from a subject comprising determining the expression level of at least one gene selected from the group consisting of CXCR2, VNN3, CYP4F3, HAL, GENE 1, FCGR3B, KCNJ15, CXCR1, STEAP4 and TNFRSF10C.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids

Abstract

The present invention relates to methods for quantifying the population of NK cells in a tissue sample. In particular, the present invention relates to a method for quantifying the population of NK cells in a tissue sample obtained from a subject comprising determining the expression level of at least one gene selected from the group consisting of KIR2DL1, KIR2DL3, NCR1, KIR3DL1, KIR3DS1, KIR3DL2, SH2D1B, CD160, GENE 2 and KIR2DL4.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids

Abstract

The present invention relates to methods for quantifying the population of T cells in a tissue sample. In particular, the present invention relates to a method for quantifying the population of T cells in a tissue sample obtained from a subject comprising determining the expression level of at least one gene selected from the group consisting of TRAT1, CD3D, THEMIS, ICOS, SIRPG, CD3G, CTLA4, CD6, CD5 and CD28.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids

Abstract

The present invention relates to methods for quantifying the population of endothelial cells in a tissue sample. In particular, the present invention relates to a method for quantifying the population of endothelial cells in a tissue sample obtained from a subject comprising determining the expression level of at least one gene selected from the group consisting of CDH5, EMCN, MYCT1, ELTD1, ROBO4, CLEC14A, VWF, ESAM, MMRN2 and KDR.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids

Abstract

The invention is within the field of human-machine interfaces. The invention relates to a haptic device capable of generating kinaesthetic feedback to a user of said device. According to the invention, the haptic device includes: a movable member (260), intended for being handled by a user; an actuator mechanism (220, 230, 240), arranged to remotely generate a mechanical stimulation force on the movable member; and a levitation mechanism, arranged to remotely generate a mechanical levitation force on the movable member, so as to keep the movable member in contactless equilibrium with respect to the levitation mechanism, the mechanical levitation force being orthogonal to the mechanical stimulation force.

IPC Classes  ?

• G06F 3/01 - Input arrangements or combined input and output arrangements for interaction between user and computer
• G06F 3/0346 - Pointing devices displaced or positioned by the userAccessories therefor with detection of the device orientation or free movement in a 3D space, e.g. 3D mice, 6-DOF [six degrees of freedom] pointers using gyroscopes, accelerometers or tilt-sensors

Abstract

The present invention relates to methods and pharmaceutical compositions for the treatment of heart failure. In particular, the present invention relates to a method of treating heart failure in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a RCN-3 polypeptide or nucleic acid molecule encoding thereof.

IPC Classes  ?

• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61P 9/04 - Inotropic agents, i.e. stimulants of cardiac contractionDrugs for heart failure

Abstract

The present invention relates to methods for quantifying the population of fibroblasts in a tissue sample. In particular, the present invention relates to a method for quantifying the population of fibroblasts in a tissue sample obtained from a subject comprising determining the expression level of at least one gene selected from the group consisting of DCN, COL6A2, 10 COL6A1, COL3A1, COL1A1, PAMR1, TAGLN and GREM1.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids

Abstract

The present invention relates to methods for quantifying the population of cells of monocytic origin in a tissue sample. In particular, the present invention relates to a method for quantifying the population of cells of monocytic origin in a tissue sample obtained from a subject comprising determining the expression level of at least one gene selected from the group consisting of CSF1R, ADAP2, RASSF4, FPR3, TFEC, PLA2G7 and KYNU.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids

Abstract

The invention relates to a device (100) for treating a liquid by cavitation, which includes: a chamber capable of containing, while in use, a volume of liquid (50) to be treated; at least one first piston (200) mounted so as to slide sealingly in said chamber between a first position and a second position; and means (400) for driving the at least one first piston between said first and second positions. The device also comprises at least one second piston (300) mounted so as to slide sealingly in said chamber between a first position and a second position. The device is designed so that, when it contains liquid with a view to using same, one of the pistons is permanently in contact with the liquid and the other piston is separated from the free surface (51) of the liquid.

IPC Classes  ?

• B01J 19/00 - Chemical, physical or physico-chemical processes in generalTheir relevant apparatus
• B01J 19/18 - Stationary reactors having moving elements inside
• C02F 1/34 - Treatment of water, waste water, or sewage with mechanical oscillations
• C02F 1/72 - Treatment of water, waste water, or sewage by oxidation
• C02F 101/36 - Organic compounds containing halogen

Abstract

The present invention relates to a method for the determination of a nucleic acid sequence by physical manipulation. The method is based on the precise determination of the localization of the replicating fork on the template by measuring the physical distance between one end of the molecule and the fork. This allows the determination of the physical location of the site where a pause or a blockage of the replication occurs, and deducing therefrom information on the sequence of the nucleic acid.

IPC Classes  ?

• C12P 19/34 - Polynucleotides, e.g. nucleic acids, oligoribonucleotides
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• C07H 21/02 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
• C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
• C07H 21/00 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

Abstract

A compound of formula (I-1) 2-amine, R′1 represents a group chosen among hydrogen and —O—R14, wherein R14 is chosen among hydrogen and a C1-C7 alkyl, and R2 is chosen among the group consisting of a C1-C7 alkyl, a C3-C6 cycloalkyl, an aryl group, and an heteroaryl group for the treatment of pathologies involving excess activity of at least one member of the kallikrein family.

IPC Classes  ?

• C07D 311/02 - Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
• A61K 31/37 - Coumarins, e.g. psoralen

Abstract

The present invention relates to methods and pharmaceutical compositions for preventing or treating inflammatory bowel diseases.

IPC Classes  ?

• A61K 35/741 - Probiotics
• C12R 1/01 - Bacteria or actinomycetales
• A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• C12N 1/20 - BacteriaCulture media therefor
• A61P 29/02 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis

Abstract

The present invention relates to a force sensor (1), comprising: - at least one measurement cell (2), each measurement cell being filled with a filling material (3) in which is embedded at least one inclusion of matter (4), - for each cell, at least one light source (5) arranged so as to illuminate the inclusion embedded in this cell, - for each cell, a measurement system comprising at least one optical measurement point (7) arranged so as to sense the light originating from the inclusion embedded in this cell, for each cell, means (9, 10) arranged so as to transform optical signals (16) originating from the measurement system of this cell into a signal representative of a force (11) exerted on this cell, this signal depending on a displacement of the inclusion embedded within the filling material of this cell.

IPC Classes  ?

• G01L 5/16 - Apparatus for, or methods of, measuring force, work, mechanical power, or torque, specially adapted for specific purposes for measuring several components of force
• G01L 1/24 - Measuring force or stress, in general by measuring variations of optical properties of material when it is stressed, e.g. by photoelastic stress analysis

Abstract

The present invention relates to a method for the determination of a nucleic acid sequence by physical manipulation. In particular, the said method comprises the steps of denaturing a double-stranded nucleic acid molecule corresponding to the said nucleic acid sequence by applying a physical force to the said molecule; and detecting a blockage of the renaturation of the double-stranded nucleic acid molecule. More specifically, the method comprises the steps of denaturing a double-stranded nucleic acid molecule corresponding to the said nucleic acid sequence by applying a physical force to the said molecule; providing a single-stranded nucleic acid molecule; renaturing the said double stranded nucleic acid molecule in the presence of the said single-stranded nucleic acid molecule; and detecting a blockage of the renaturation of the double-stranded nucleic acid.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• C12P 19/34 - Polynucleotides, e.g. nucleic acids, oligoribonucleotides
• G01N 33/00 - Investigating or analysing materials by specific methods not covered by groups
• C07H 21/02 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
• C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical

Abstract

The invention relates to a method for giving a theme to a route taken by a vehicle, including steps of: receiving (21) an experience originating from a base of predefined experiences, said experience being associated with a plurality of milestones; receiving (22) a route originating from a navigation system of the vehicle; selecting (23), for each milestone of said experience, a place from a database of places, so that each of the places is associated with a milestone and is located in proximity to the route; receiving (24) geopositioning information originating from the navigation system, as the vehicle travels along the route, and indicating an actual position of the vehicle; and, when the geopositioning information coincides with a selected place, transmitting a signal ordering at least one medium associated with the selected place and the received experience to be broadcast (25) via an interface of the vehicle.

IPC Classes  ?

• G01C 21/36 - Input/output arrangements for on-board computers

Abstract

The invention relates to a method for the permanent electrostatic doping of a layer of a conductive or non-conductive material deposited on a solid substrate, to the doped material produced according to said method, and to the use of such a material.

IPC Classes  ?

• C03C 17/22 - Surface treatment of glass, e.g. of devitrified glass, not in the form of fibres or filaments, by coating with other inorganic material
• C03C 17/23 - Oxides
• H01L 21/20 - Deposition of semiconductor materials on a substrate, e.g. epitaxial growth
• H01L 23/00 - Details of semiconductor or other solid state devices

Abstract

A fluidic device comprising at least: a/ a solid matrix (5), b/ a textile component (4), embedded in said matrix and mechanically cohesive with said matrix, c/ at least one channel (6) embedded in said matrix and entangled with said textile component (4), said channel (6) being at least partly open. A method for making a fluidic device comprising providing a textile component (4) comprising support fibers (1.1), (1.2) and at least a movable fiber (2) entangled with said textile (4), embedding at least part of said textile 4 and part of said movable fiber (2), in a matrix precursor material (5), applying a treatment in order to obtain a solid matrix (5).

IPC Classes  ?

• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers
• B29C 67/00 - Shaping techniques not covered by groups , or
• B29C 70/02 - Shaping composites, i.e. plastics material comprising reinforcements, fillers or preformed parts, e.g. inserts comprising combinations of reinforcements and fillers incorporated in matrix material, forming one or more layers, with or without non-reinforced or non-filled layers
• F16L 11/08 - Hoses, i.e. flexible pipes made of rubber or flexible plastics with reinforcements embedded in the wall
• B29C 67/20 - Shaping techniques not covered by groups , or for porous or cellular articles, e.g. of foam plastics, coarse-pored
• B32B 5/02 - Layered products characterised by the non-homogeneity or physical structure of a layer characterised by structural features of a layer comprising fibres or filaments
• B32B 5/12 - Layered products characterised by the non-homogeneity or physical structure of a layer characterised by structural features of a layer comprising fibres or filaments characterised by the relative arrangement of fibres or filaments of adjacent layers
• B32B 17/04 - Layered products essentially comprising sheet glass, or fibres of glass, slag or the like in the form of fibres or filaments bonded with or embedded in a plastic substance
• D03D 11/02 - Fabrics formed with pockets, tubes, loops, folds, tucks or flaps

Abstract

A minifluidic device comprising a matrix, an elongated guiding duct (109) embedded at least in part in said matrix, with at least one port to the outside of the matrix, a movable fiber (104) at least partly contained in said guiding duct (109), and able to undergo within said guiding duct (109), and at least along some part of said fiber (104), at least one action selected among a sliding, or a deformation, or a rotation and at least one of the movable fiber or the guiding duct is elastic or is non linear along at least part of its length, or at least part of the matrix is elastic.

IPC Classes  ?

• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers
• F16K 99/00 - Subject matter not provided for in other groups of this subclass

Abstract

The invention relates to polypeptides containing a cytoplasmic domain ending with a MAST-2 binding domain, from 11 to 13 residues, the first two residues of which are S and W, and the last four residues of which are Q, T, R and L, the polypeptides presenting a high affinity for the PDZ domain of the human MAST2 protein. The invention also relates to polynucleotides, vectors, lentiviral particles, cells as well as compositions containing the same. The invention is also directed to the use of the polypeptides, polynucleotides, vectors, lentiviral particles, cells and compositions in the treatment and/or prevention of a disease, disorder or condition, which alters the Central Nervous System (CNS) and/or the Peripheral Nervous System (PNS). The invention also concerns molecular signatures of cellular genes to determine the neurosurvival and/or neuroprotection activity of a molecule.

IPC Classes  ?

• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
• C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
• C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving virus or bacteriophage

Abstract

The invention is from the field of assistance in establishing a medical diagnosis and relates to a method for assisting in establish a diagnosis for a patient on the basis of at least one identified sign by relying on a computerized knowledge base comprising a medical ontology. The medical ontology includes: a list of signs, forming a "sign" class, a list of medical conditions, forming a "medical condition" class, and a first set of logical relationships between the signs and the medical conditions, each logical relationship establishing a correlative link between a sign and a medical condition. The method according to the invention includes: a step (503) of searching for medical conditions linked at least to one of the signs identified by means of the first set of logical relationships, and a step (504) of identifying potential signs, in which, for each potential medical condition, all the signs linked by a correlative link to said potential medical condition are identified by means of the first set of logical relationships.

IPC Classes  ?

• G06F 19/00 - Digital computing or data processing equipment or methods, specially adapted for specific applications (specially adapted for specific functions G06F 17/00;data processing systems or methods specially adapted for administrative, commercial, financial, managerial, supervisory or forecasting purposes G06Q;healthcare informatics G16H)

Abstract

The present invention relates to methods and pharmaceutical compositions for the treatment of cystic fibrosis. In particular, the present invention relates to a method of treating cystic fibrosis in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a nucleic acid miR-9 inhibitor.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 31/712 - Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
• A61P 11/00 - Drugs for disorders of the respiratory system

Abstract

The present invention relates to methods and pharmaceutical compositions for the treatment of cystic fibrosis. In particular, the present invention relates to a method of treating cystic fibrosis in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a nucleic acid miR-9 inhibitor.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 31/712 - Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
• A61P 11/00 - Drugs for disorders of the respiratory system